Evidence map›Paper›PMID 35045829›Full record

ArticleBMC microbiology2022

Diffusion of OXA-48 carbapenemase among urinary isolates of Klebsiella pneumoniae in non-hospitalized elderly patients.

Sandra Šuto, Branka Bedenić, Saša Likić, Sara Kibel, Maja Anušić, Vladimira Tičić, Gernot Zarfel, Andrea Grisold, Ivan Barišić, Jasmina Vraneš

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Characterization ofAntibiotics (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Complete genome sequence of the OXA-48-producingMicrobiology resource announcements · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Exploring the Antibiotic Resistance Profile of ClinicalAntibiotics (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Sandra ŠutoDepartment of Clinical Microbiology, Andrija Štampar Public Health Institute, Zagreb, Croatia.
Branka BedenićDepartment of Microbiology, University of Zagreb School of Medicine, Kišpatićeva 12, Zagreb, Croatia. branka.bedenic@kbc-zagreb.hr.
Saša LikićDepartment of Microbiology, University of Zagreb School of Medicine, Kišpatićeva 12, Zagreb, Croatia.
Sara KibelDepartment of Transfusiology, University Hospital Center Osijek, Osijek, Croatia.
Maja AnušićDepartment of Clinical Microbiology, Andrija Štampar Public Health Institute, Zagreb, Croatia.
Vladimira TičićDepartment of Clinical Microbiology, Andrija Štampar Public Health Institute, Zagreb, Croatia.
Gernot ZarfelInstitute for Hygiene, Microbiology and Environmental Medicine, Medical University Graz, Graz, Austria.
Andrea GrisoldInstitute for Hygiene, Microbiology and Environmental Medicine, Medical University Graz, Graz, Austria.
Ivan BarišićAustrian Institute for Technology, Vienna, Austria.
Jasmina VranešDepartment of Clinical Microbiology, Andrija Štampar Public Health Institute, Zagreb, Croatia.
Andrija Stampar Teaching Institute of Public Health · HRMedical University of Graz · ATUniversity of Zagreb · HRAustrian Institute of Technology · ATUniversity of Osijek · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently, a dramatic increase of Klebsiella pneumoniae positive for OXA-48 β-lactamases was observed first in the hospital setting and later in the long-term care facilities (LTCFs) and community in the Zagreb County, particularly, in urinary isolates. The aim of the study was to analyse the epidemiology and the mechanisms of antibiotic resistance of OXA-48 carbapenemase producing K. pneumoniae strains isolated from urine of non-hospitalized elderly patients.

resultsThe isolates were classified into two groups: one originated from the LTCFs and the other from the community. Extended-spectrum β-lactamases (ESBLs) were detected by double disk-synergy (DDST) and combined disk tests in 55% of the isolates (51/92). The ESBL-positive isolates exhibited resistance to expanded-spectrum cephalosporins (ESC) and in majority of cases to gentamicin. LTCFs isolates showed a significantly lower rate of additional ESBLs and consequential resistance to ESC and a lower gentamicin resistance rate compared to the community isolates, similarly to hospital isolates in Zagreb, pointing out to the possible transmission from hospitals.ESBL production was associated with group 1 of CTX-M or SHV-12 β-lactamases. Ertapenem resistance was transferable from only 12 isolates. bla

conclusionsThis study showed eruptive and extensive diffusion of OXA-48 carbapenemase to LTCFs and community population in Zagreb County, particularly affecting patients with UTIs and urinary catheters. On the basis of susceptibility testing, β-lactamase production, conjugation experiments, MLST and plasmid characterization it can be concluded that there was horizontal gene transfer between unrelated isolates, responsible for epidemic spread of OXA-48 carbapenemase in the LTCFs and the community The rapid spread of OXA-48 producing K. pneumoniae points out to the shortcomings in the infection control measures.

Indexed as

AgedAged, 80 and overAnti-Bacterial Agentsbeta-LactamasesCroatiaDrug Resistance, Multiple, BacterialFemaleHospitalizationHumansKlebsiella InfectionsKlebsiella pneumoniaeMaleMicrobial Sensitivity TestsMiddle AgedMultilocus Sequence TypingAnti-Bacterial Agentsbeta-LactamasesoxacillinaseKlebsiella pneumoniaeLong-term care facilityOXA-48ResistanceUrinary tract infection

Identifiers

PMID35045829
PMCPMC8767700
OpenAlexW4205277127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.